,ticker,date,time,headline,neg,neu,pos,compound
0,BIIB,2021-04-13,05:27PM,"Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study",0.0,0.714,0.286,0.5574
1,BIIB,2021-04-12,04:40PM,Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug,0.0,1.0,0.0,0.0
2,BIIB,2021-04-12,04:30PM,"Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen",0.0,1.0,0.0,0.0
3,BIIB,2021-04-12,11:45AM,"Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out",0.139,0.861,0.0,-0.2732
4,BIIB,2021-04-12,07:00AM,Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint,0.0,1.0,0.0,0.0
5,BIIB,2021-04-09,04:30PM,Biogen Announces Two New Nominees for Election to Board of Directors,0.0,1.0,0.0,0.0
6,BIIB,2021-04-08,04:20PM,Biotech Stocks Could Use A Win  Will The First Quarter Offer That?,0.0,0.725,0.275,0.5859
7,BIIB,2021-04-08,01:31PM,Is It Too Late to Buy Biogen (BIIB) Stock?,0.0,1.0,0.0,0.0
8,BIIB,2021-04-08,11:12AM,"Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis",0.0,0.789,0.211,0.4939
9,BIIB,2021-04-08,07:00AM,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis,0.083,0.673,0.244,0.6124
10,BIIB,2021-04-07,07:30AM,The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis,0.0,0.777,0.223,0.5574
11,BIIB,2021-04-06,06:00AM,Is This Another Strike Against Biogen's Alzheimer's Drug?,0.176,0.824,0.0,-0.128
12,BIIB,2021-04-03,11:56PM,How Biogen Makes Money?,0.0,1.0,0.0,0.0
13,BIIB,2021-03-25,04:45PM,Two Things That Could Stoke Biogen Stock  That Aren't Aducanumab,0.0,1.0,0.0,0.0
14,BIIB,2021-03-25,03:13PM,Biogen Stock Is More More Than Its Alzheimers Treatment. What Else to Watch.,0.0,1.0,0.0,0.0
15,BIIB,2021-03-25,08:30AM,"Techking Custom-made Tires Come to Full Play in Australia, Well Recognized by Rio Tinto and XCMG",0.0,0.757,0.243,0.5423
16,BIIB,2021-03-21,10:35AM,Is Biogen (BIIB) Stock A Buy or Sell?,0.0,1.0,0.0,0.0
17,BIIB,2021-03-21,06:11AM,"3 Reasons to Buy Sage Therapeutics, and 1 Reason to Pass",0.0,1.0,0.0,0.0
18,BIIB,2021-03-19,04:33PM,Lillys and Biogens Alzheimers Drugs Have a Way to Go. There Are Still Reasons to Be Hopeful.,0.0,0.82,0.18,0.5106
19,BIIB,2021-03-18,09:39AM,Dont Lose Sight of Biogens Depression Drug. How It Could Send the Stock Much Higher.,0.195,0.686,0.119,-0.3489
20,BIIB,2021-03-17,06:00AM,"Before You Buy Biogen, Stop and Consider These 3 Things",0.216,0.784,0.0,-0.296
21,BIIB,2021-03-15,04:52PM,Eli Lilly Said Its Alzheimers Data Were Positive. The Stock Market Says Otherwise.,0.0,0.769,0.231,0.5574
22,BIIB,2021-03-15,07:47AM,Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing,0.228,0.523,0.248,0.079
23,BIIB,2021-03-10,09:29AM,Eli Lilly Has More Positive Data on Its Combination Covid-19 Antibody Therapy,0.0,0.739,0.261,0.5984
24,BIIB,2021-03-09,04:55PM,Why A Controversial Biogen Drug Could Become A Major Blockbuster,0.154,0.513,0.333,0.4767
25,BIIB,2021-03-09,04:17PM,Why A Controversial Biogen Drug Could Become A Major Blockbuster,0.154,0.513,0.333,0.4767
26,BIIB,2021-03-08,09:20AM,"Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' term loan; stable outlook",0.0,0.833,0.167,0.296
27,BIIB,2021-03-07,01:53AM,Here's What Biogen Inc.'s (NASDAQ:BIIB) Shareholder Ownership Structure Looks Like,0.0,0.783,0.217,0.3612
28,BIIB,2021-03-05,11:30AM,Biogen Inc. (BIIB) Down 1.4% Since Last Earnings Report: Can It Rebound?,0.0,1.0,0.0,0.0
29,BIIB,2021-03-05,09:10AM,Eli Lilly Will Unveil Alzheimers Drug Data Next Week. What to Watch.,0.0,1.0,0.0,0.0
30,BIIB,2021-03-04,08:06AM,Biogen to build gene therapy manufacturing center in North Carolina,0.0,1.0,0.0,0.0
31,BIIB,2021-03-04,07:47AM,"Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina",0.0,1.0,0.0,0.0
32,BIIB,2021-03-01,05:11PM,Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal,0.0,1.0,0.0,0.0
33,BIIB,2021-02-26,01:16PM,7 Stocks to Sell for March,0.0,1.0,0.0,0.0
34,BIIB,2021-02-24,04:28PM,10 Cheap Stocks To Invest In (February 2021),0.0,1.0,0.0,0.0
35,BIIB,2021-02-24,07:30AM,Life Science Cares and Biogen Foundation Help Launch Food For Frees Just Eats Program,0.0,0.582,0.418,0.7845
36,BIIB,2021-02-24,06:53AM,Sage Therapeutics Rises After Swing to Profit on Biogen Deal,0.0,0.756,0.244,0.4404
37,BIIB,2021-02-23,06:30AM,Where Will Biogen Be in 5 Years?,0.0,1.0,0.0,0.0
38,BIIB,2021-02-20,06:12AM,Is Biogen Stock a Buy?,0.0,1.0,0.0,0.0
39,BIIB,2021-02-16,04:16PM,Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs?,0.0,1.0,0.0,0.0
40,BIIB,2021-02-12,10:00AM,"Eli Lilly Executives Enthusiastic About Alzheimers Drug, Analyst Says",0.0,0.714,0.286,0.4939
41,BIIB,2021-02-12,09:23AM,Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?,0.162,0.634,0.204,0.1531
42,BIIB,2021-02-12,06:25AM,Why Is Everyone Talking About Biogen Stock?,0.0,1.0,0.0,0.0
43,BIIB,2021-02-11,04:23PM,This Dollar-Stock Biotech Popped In Bullish Volume On Its Alzheimer's News,0.0,1.0,0.0,0.0
44,BIIB,2021-02-11,12:00PM,Why Alkermes' Q4 Results Were Better Than They Might Seem,0.0,0.756,0.244,0.4404
45,BIIB,2021-02-11,09:13AM,"The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte",0.0,1.0,0.0,0.0
46,BIIB,2021-02-11,08:03AM,Biogen Announces the Expiration Date Results of Its Cash Tender Offer,0.0,1.0,0.0,0.0
47,BIIB,2021-02-11,08:00AM,Biogen Announces the Expiration Date Results of Its Private Exchange Offer,0.0,1.0,0.0,0.0
48,BIIB,2021-02-11,07:30AM,Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups,0.0,0.632,0.368,0.7506
49,BIIB,2021-02-10,01:02PM,Biogen Announces the Pricing Terms of its Cash Tender Offer,0.0,1.0,0.0,0.0
50,BIIB,2021-02-10,01:00PM,Biogen Announces the Pricing Terms of Its Private Exchange Offer,0.0,1.0,0.0,0.0
51,BIIB,2021-02-10,11:57AM,"Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates",0.0,1.0,0.0,0.0
52,BIIB,2021-02-09,06:27AM,Should You Sell Cassava Sciences Stock Now?,0.0,1.0,0.0,0.0
53,BIIB,2021-02-08,08:22AM,"What to Know Before Buying Cassava Sciences, the Hot Alzheimers Stock",0.0,1.0,0.0,0.0
54,BIIB,2021-02-07,01:44PM,Biogens Alzheimers Drug Faces a Big Test. What to Know.,0.0,1.0,0.0,0.0
55,BIIB,2021-02-07,01:27PM,The Other Pandemic: What to Do About the Coming Alzheimers Crisis,0.291,0.709,0.0,-0.6249
56,BIIB,2021-02-06,01:52PM,"Barron's Picks And Pans: Amazon, Biogen, Casey's General Stores, Hilton And More",0.0,0.866,0.134,0.1779
57,BIIB,2021-02-05,01:15AM,Have Insiders Been Buying Biogen Inc. (NASDAQ:BIIB) Shares?,0.0,0.761,0.239,0.296
58,BIIB,2021-02-04,04:10PM,10 Cheap Healthcare Stocks To Buy Now,0.0,1.0,0.0,0.0
59,BIIB,2021-02-04,11:11AM,Biogen Inc. -- Moody's assign's Baa1 to Biogen's notes; on review for downgrade,0.0,1.0,0.0,0.0
60,BIIB,2021-02-04,09:10AM,Biogen: Debt Overview,0.556,0.444,0.0,-0.3612
61,BIIB,2021-02-04,09:02AM,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only,0.0,0.877,0.123,0.2732
62,BIIB,2021-02-04,09:00AM,Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors,0.0,0.87,0.13,0.2732
63,BIIB,2021-02-04,04:34AM,Biogens 4Q Earnings Miss Street Estimates; Shares Fall 5.2%,0.44,0.41,0.15,-0.6408
64,BIIB,2021-02-03,04:40PM,Biogen Crumbles; Disappointing 2021 Outlook Calls For A 'Sharp Decline',0.286,0.714,0.0,-0.4939
65,BIIB,2021-02-03,01:01PM,Biogen Inc (BIIB) Q4 2020 Earnings Call Transcript,0.0,1.0,0.0,0.0
66,BIIB,2021-02-03,12:52PM,"Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates",0.186,0.814,0.0,-0.1531
67,BIIB,2021-02-03,11:30AM,Why Biogen's Q4 Results Were a Bust,0.0,1.0,0.0,0.0
68,BIIB,2021-02-03,10:25AM,"Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More",0.0,0.764,0.236,0.5267
69,BIIB,2021-02-03,10:04AM,Biogen Stock Is Falling Because Earnings Guidance Came Up Short,0.151,0.849,0.0,-0.1531
70,BIIB,2021-02-03,08:39AM,Biogen Off on Weaker-Than-Expected 2021 Forecast,0.0,1.0,0.0,0.0
71,BIIB,2021-02-03,08:35AM,Biogen Inc. (BIIB) Misses Q4 Earnings Estimates,0.241,0.759,0.0,-0.2263
72,BIIB,2021-02-03,08:21AM,Perrigo will not receive $400 million milestone payment,0.0,1.0,0.0,0.0
73,BIIB,2021-02-03,07:19AM,Biogen: Q4 Earnings Insights,0.0,1.0,0.0,0.0
74,BIIB,2021-02-03,06:15AM,"Biogen, Inc. to Host Earnings Call",0.0,1.0,0.0,0.0
75,BIIB,2021-02-02,10:12AM,Preview: Biogen's Earnings,0.0,1.0,0.0,0.0
76,BIIB,2021-02-01,09:40AM,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?,0.0,0.776,0.224,0.3818
77,BIIB,2021-02-01,07:30AM,Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis,0.0,0.795,0.205,0.4767
78,BIIB,2021-01-31,03:40AM,Biogen Shares Gain 5.5% As FDA Extends Review Period For Alzheimers Drug,0.0,0.559,0.441,0.7269
79,BIIB,2021-01-29,04:23PM,Biogen Surges To Two-Month High On Delayed Review For Alzheimer's Drug,0.16,0.84,0.0,-0.2263
80,BIIB,2021-01-29,01:52PM,Why Biogen Stock Popped Today,0.0,1.0,0.0,0.0
81,BIIB,2021-01-29,11:40AM,Biogen shares jump 9% after FDA extends review period for Alzheimer's treatment,0.0,0.73,0.27,0.4019
82,BIIB,2021-01-29,11:16AM,"Lilly Reports Strong Sales, Boosted by Covid Antibodies",0.0,0.508,0.492,0.7003
83,BIIB,2021-01-29,10:38AM,The FDA Delayed Its Decision on Biogens Alzheimers Drug. The Stock Is Up 10%.,0.128,0.872,0.0,-0.2263
84,BIIB,2021-01-29,09:15AM,Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months,0.0,0.804,0.196,0.296
85,BIIB,2021-01-29,09:10AM,U.S. FDA extends review period for Biogen's Alzheimer's drug,0.0,0.842,0.158,0.128
86,BIIB,2021-01-29,07:41AM,U.S. FDA extends review period for Biogen's Alzheimer's drug to June,0.0,0.87,0.13,0.128
87,BIIB,2021-01-29,07:30AM,Biogen and Eisai Announce FDAs 3-Month Extension of Review Period for the Biologics License Application for Aducanumab,0.0,1.0,0.0,0.0
88,BIIB,2021-01-29,05:47AM,Biogen Analysts Laud FDA Extension of Alzheimer's Drug Review,0.0,1.0,0.0,0.0
89,BIIB,2021-01-28,04:55PM,How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?,0.0,0.671,0.329,0.7089
90,BIIB,2021-01-28,07:15AM,Is Biogen Stock A Buy After As Alzheimer's Drug Heads To Full FDA?,0.0,1.0,0.0,0.0
91,BIIB,2021-01-27,12:10PM,Why the Earnings Surprise Streak Could Continue for Biogen Inc. (BIIB),0.0,0.826,0.174,0.2732
92,BIIB,2021-01-27,10:08AM,"Vir Will Test Its Covid-19 Antibody With Eli Lillys, Sending Shares Up Again",0.0,0.845,0.155,0.296
93,BIIB,2021-01-27,06:50AM,2 Biotech Stocks With Major Potential Catalysts in 2021,0.0,1.0,0.0,0.0
94,BIIB,2021-01-22,05:36AM,4 Stocks Warren Buffett Is Likeliest to Sell in 2021,0.0,1.0,0.0,0.0
95,BIIB,2021-01-20,10:35AM,Eli Lilly Stock Is Surging on Hope for Alzheimers Drug. Analyst Says It Wont Last.,0.0,0.828,0.172,0.4404
96,BIIB,2021-01-19,01:29PM,Top Healthcare Stocks for February 2021,0.0,0.735,0.265,0.2023
97,BIIB,2021-01-15,10:39AM,"The Zacks Analyst Blog Highlights: PayPal, Exxon Mobil, Goldman Sachs, Charter Communications and Biogen",0.0,1.0,0.0,0.0
98,BIIB,2021-01-14,03:29PM,Biogen Stock Is Jumping Because There May Be Hope for Its Alzheimers Drug Yet,0.0,0.818,0.182,0.4404
99,BIIB,2021-01-13,09:35AM,"Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day",0.0,0.896,0.104,0.2732
